Gregory J. Riely, MD, PhD, on the Clinical Impact of Targeting NTRK Gene Fusion in Advanced Cancers

Posted: Wednesday, September 1, 2021

Gregory J. Riely, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the dramatic changes in the way patients with advanced tumors are treated, the impact of NTRK fusions, and the drugs that can target them. Dr. Riely specifically focused on non–small cell lung cancer, where some of the greatest advances have occurred, thanks to long-lasting responses to targeted therapies for ALK fusions and EGFR mutations.